Rheumatoid arthritis, new standards of care: Nursing implications of infliximab

  • Risley S
  • Thomas M
  • Bray V
  • 2


    Mendeley users who have this article in their library.
  • 3


    Citations of this article.


The apparent central role of tumour necrosis factor alpha (TNFα) in the pathophysiology of rheumatoid arthritis suggests that anti-TNFα therapy may provide prolonged therapeutic benefits. This article describes the use of Infliximab (REMICADE®, Centocor, Inc. Malvern, PA), a chimeric monoclonal antibody that binds with high affinity and specificity to TNFα. Patient management and education, infusion preparation, dosing and administration, and patient monitoring are all explored in relation to nursing care. Finally, the health care professional's perspective is given. © 2004 Elsevier Ltd. All rights reserved.

Author-supplied keywords

  • Anti-tumour necrosis factor alpha (TNFα)
  • Infliximab
  • Rheumatoid arthritis

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Susan Risley

  • Mary Ann Thomas

  • Vance Bray

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free